Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
9 hedge funds and large institutions have $24.3M invested in Anebulo Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
2.09% more ownership
Funds ownership: 17.95% → 20.03% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 10 → 9 (-1)
18% less capital invested
Capital invested by funds: $29.5M → $24.3M (-$5.21M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
+$2.93M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$26.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.15K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$1.48M |
| 2 |
BlackRock
New York
|
-$502 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $17.5M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $3.64M | +$2.93M | +700,000 | New |
|
|
MP
3
Mangrove Partners
Greenwich,
Connecticut
| $2.08M | – | – | – |
|
|
IC
4
Ikarian Capital
Dallas,
Texas
| $942K | – | – | – |
|
|
BFM
5
Boothbay Fund Management
New York
| $90K | – | – | – |
|
|
6
BlackRock
New York
| $38K | -$502 | -120 | -2% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $37K | +$26.7K | +6,385 | +845% |
|
|
8
UBS Group
Zurich,
Switzerland
| $15K | +$3.15K | +753 | +35% |
|
|
LCM
9
Laurion Capital Management
New York
| – | -$1.48M | -219,583 | Closed |
|
|
10
Wells Fargo
San Francisco,
California
| – | +$4 | +1 | +5% |
|
ANEB Hedge Fund Activity: Q2 2022 in Review
9 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q2 2022, worth a combined $24.3M — down 18% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ANEB and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was LVW Advisors, opening a new position worth an estimated $2.93M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $1.48M sold.
- 9 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q2 2022, down from 10 in Q1 2022.
- Funds reported $24.3M of Anebulo Pharmaceuticals stock for Q2 2022, down 18% quarter-over-quarter.
- 1 fund opened new Anebulo Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Anebulo Pharmaceuticals buyer in Q2 2022 was LVW Advisors, an estimated $2.93M added.
- The largest Anebulo Pharmaceuticals seller in Q2 2022 was Laurion Capital Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2022.